Drug Profile
Research programme: Rpn13 inhibitors - Pi Therapeutics
Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer Pi Therapeutics
- Class Antineoplastics
- Mechanism of Action ADRM1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cervical cancer; Head and neck cancer; Multiple myeloma
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cervical-cancer in Israel (PO)
- 28 May 2021 No recent reports of development identified for preclinical development in Head-and-neck-cancer in Israel (PO)
- 28 May 2021 No recent reports of development identified for preclinical development in Multiple-myeloma in Israel (PO)